Pulmatrix (PULM) EBITDA Margin (2014 - 2024)
Pulmatrix (PULM) posted EBITDA Margin of 65066.67% for Q4 2024, down 8862.89% sequentially from 725.96% in Q3 2024, and down 6496562.0% YoY from N/an in Q1 2024.
Pulmatrix (PULM) EBITDA Margin (2014 - 2024) Analysis & Trends
Pulmatrix has reported EBITDA Margin for 11 years, with the latest figure at 65066.67% in Q4 2024.
- Quarterly EBITDA Margin fell 6496562.0% year-over-year to 65066.67% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 125.07% (up 7690.0% YoY) and the FY2024 annual result came in at 125.07%, up 7690.0% from the prior year.
- EBITDA Margin declined to 65066.67% in Q4 2024 per PULM's latest filing, from 725.96% in the prior quarter.
- Over five years, EBITDA Margin peaked at 12.69% in Q1 2024 and troughed at 65066.67% in Q4 2024.
- A 5-year average of 3539.48% and a median of 262.83% in 2022 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2024: EBITDA Margin surged 63340 bps in 2022, then slumped 6496562 bps in 2024.
- Over 5 years, EBITDA Margin stood at 133.7% in 2020, then plunged by 563 bps to 886.62% in 2021, then jumped by 71 bps to 253.22% in 2022, then soared by 60 bps to 101.04% in 2023, then tumbled by 64294 bps to 65066.67% in 2024.
- According to Business Quant data, EBITDA Margin over the past three periods registered 65066.67%, 725.96%, and 380.22% for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 19.75% |
| 10 | Pulmatrix | 5.62 Mn | 5.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -65,066.67% |
| Sep 30, 2024 | -725.96% |
| Jun 30, 2024 | -380.22% |
| Mar 31, 2024 | 12.69% |
| Dec 31, 2023 | -101.04% |
| Sep 30, 2023 | -224.70% |
| Jun 30, 2023 | -216.43% |
| Mar 31, 2023 | -305.87% |
| Dec 31, 2022 | -253.22% |
| Sep 30, 2022 | -272.44% |
| Jun 30, 2022 | -342.52% |
| Mar 31, 2022 | -427.84% |
| Dec 31, 2021 | -886.62% |
| Sep 30, 2021 | -766.14% |
| Jun 30, 2021 | -170.76% |
| Mar 31, 2021 | -293.88% |
| Dec 31, 2020 | -133.70% |
| Sep 30, 2020 | -29.21% |
| Jun 30, 2020 | -33.54% |
| Mar 31, 2020 | -171.51% |